Investigations using CRISPR technology to create drug‐resistant ovarian cancer cell lines have demonstrated that the absence of EXO1 can reverse drug resistance and improve sensitivity to cisplatin and doxorubicin, and it was therefore identified as a potential therapeutic target.45 This evidence concerns the gene EXO1 and ovarian carcinoma.